SV

Street Verdict

Analyst Scorecard

A record of what Dipan Mehta said publicly, with the source. Not advice.

Pending — not yet graded
“Dipan Mehta is positive on Aurobindo Pharma, viewing recent Form 483 observations as not a major concern due to diversified manufacturing. He sees the broader pharma sector as a safe bet in volatile times, supported by tailwinds like rupee depreciation, opportunities in weight-loss drugs, and improved capital allocation.”
Aurobindo Pharma LimitedBullishCalled 18 Mar 2026
Verdict:PENDING

This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.

Read the original articleSee Dipan Mehta’s full track record